Iradimed (NASDAQ:IRMD) Updates FY 2025 Earnings Guidance

Iradimed (NASDAQ:IRMD) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.710-1.810 for the period, compared to the consensus earnings per share estimate of 1.750. The company issued revenue guidance of $78.0 million-$82.0 million, compared to the consensus revenue estimate of $80.7 million. Iradimed also updated its Q1 2025 guidance to 0.390-0.430 EPS.

Iradimed Stock Performance

IRMD opened at $55.23 on Friday. Iradimed has a one year low of $40.18 and a one year high of $63.29. The company has a market cap of $699.76 million, a P/E ratio of 37.83 and a beta of 0.82. The business’s 50-day simple moving average is $57.20 and its 200-day simple moving average is $52.10.

Iradimed (NASDAQ:IRMD) last released its quarterly earnings data on Thursday, February 13th. The medical equipment provider reported $0.40 EPS for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.05). Iradimed had a net margin of 26.12% and a return on equity of 23.99%. As a group, analysts predict that Iradimed will post 1.52 earnings per share for the current fiscal year.

Iradimed Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 5th. Stockholders of record on Monday, February 24th will be issued a $0.17 dividend. The ex-dividend date is Monday, February 24th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.23%. This is an increase from Iradimed’s previous quarterly dividend of $0.15. Iradimed’s dividend payout ratio is presently 41.10%.

Analysts Set New Price Targets

A number of analysts recently issued reports on IRMD shares. StockNews.com cut Iradimed from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Roth Mkm reissued a “buy” rating and issued a $72.00 target price (up from $60.00) on shares of Iradimed in a research report on Friday.

Insider Activity at Iradimed

In other Iradimed news, CFO John Glenn sold 2,500 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total transaction of $135,450.00. Following the completion of the sale, the chief financial officer now directly owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. This trade represents a 36.32 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 37.10% of the company’s stock.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.